Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. Although the use of colony-stimulating factors (CSFs) is well established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents.